ATE426594T1 - Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase - Google Patents

Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase

Info

Publication number: ATE426594T1
Authority: AT; Austria
Prior art keywords: coa reductase; reductase inhibitors; sub; img; hmg
Prior art date: 2002-01-31

Application number

AT03734716T

Other languages

English (en)

Inventor

Murat Acemoglu

Bernhard Riss

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-31

Filing date

2003-01-30

Publication date

2009-04-15

2003-01-30 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2009-04-15 Application granted granted Critical

2009-04-15 Publication of ATE426594T1 publication Critical patent/ATE426594T1/de

Links

238000004519 manufacturing process Methods 0.000 title abstract 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
150000002596 lactones Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Enzymes And Modification Thereof (AREA)
Indole Compounds (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT03734716T 2002-01-31 2003-01-30 Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase ATE426594T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US35378702P	2002-01-31	2002-01-31

Publications (1)

Publication Number	Publication Date
ATE426594T1 true ATE426594T1 (de)	2009-04-15

Family

ID=27663254

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03734716T ATE426594T1 (de)	2002-01-31	2003-01-30	Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase

Country Status (22)

Country	Link
US (2)	US7371865B2 (de)
EP (1)	EP1472228B1 (de)
JP (1)	JP4524111B2 (de)
KR (1)	KR20040081161A (de)
CN (1)	CN1305853C (de)
AT (1)	ATE426594T1 (de)
AU (1)	AU2003226971B2 (de)
BR (1)	BR0307303A (de)
CA (1)	CA2472776C (de)
CO (1)	CO5601005A2 (de)
DE (1)	DE60326819D1 (de)
EC (1)	ECSP045214A (de)
ES (1)	ES2323267T3 (de)
IL (1)	IL162980A (de)
MX (1)	MXPA04007396A (de)
NO (1)	NO327091B1 (de)
NZ (1)	NZ534232A (de)
PL (1)	PL370658A1 (de)
PT (1)	PT1472228E (de)
RU (1)	RU2299196C2 (de)
WO (1)	WO2003064392A1 (de)
ZA (1)	ZA200405322B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004072040A1 (en) *	2003-02-12	2004-08-26	Ciba Specialty Chemicals Holding Inc.	Crystalline forms of pitavastatin calcium
KR20060006052A (ko) *	2003-04-24	2006-01-18	다이셀 가가꾸 고교 가부시끼가이샤	에틸(3ｒ,5ｓ,6ｅ)-7-[2-시클로프로필-4-(4-플루오로페닐)퀴놀린-3-일]-3,5-디히드록시-6-헵테노에이트의 제조 방법
TWI328006B (en) *	2003-12-26	2010-08-01	Nissan Chemical Ind Ltd	Crystal form of quinoline compound and process for its production
EP1817027A2 (de) *	2004-09-27	2007-08-15	Ranbaxy Laboratories Limited	Verfahren zur herstellung von enantiomerisch reinem fluvastatinnatrium und einer neuen polymorphen form davon
SI2024341T1 (sl) *	2006-05-03	2016-04-29	Msn Laboratories Private Limited	Novi postopek za statine in njihove farmacevtsko sprejemljive soli
US8404841B2 (en) *	2006-10-09	2013-03-26	Msn Laboratories Limited	Process for the preparation of statins and their pharmaceutically acceptable salts thereof
KR20090018964A (ko)	2007-04-18	2009-02-24	테바 파마슈티컬 인더스트리즈 리미티드	Ｈｍｇ-ｃｏａ 환원 효소 억제제의 중간체의 제조 방법
JP2010501643A (ja) *	2007-07-12	2010-01-21	テバファーマシューティカルインダストリーズリミティド	薄膜蒸発及び化学的手法によるロスバスタチン中間体の精製
US8487105B2 (en) *	2009-01-19	2013-07-16	Msn Laboratories Limited	Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
KR101160152B1 (ko) *	2009-02-24	2012-06-27	한미사이언스 주식회사	스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
EP2526099B1 (de)	2010-01-18	2016-03-30	MSN Laboratories Limited	Verbessertes verfahren zur herstellung von amid-zwischenprodukten und seine anwendung
WO2011104725A2 (en) *	2010-02-23	2011-09-01	Cadila Healthcare Limited	Hmg-coa reductase inhibitors and process for the preparation thereof
EP2383260A3 (de)	2010-04-30	2011-12-28	Dipharma Francis S.r.l.	Verfahren zur Herstellung von Statine
WO2011141934A1 (en)	2010-05-13	2011-11-17	Matrix Laboratories Ltd.	An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
WO2012002741A2 (en) *	2010-07-01	2012-01-05	Yuhan Corporation	Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
WO2012063254A1 (en) *	2010-11-12	2012-05-18	Hetero Research Foundation	Novel polymorphs of pitavastatin calcium
EP2785851A2 (de)	2011-11-28	2014-10-08	Mylan Laboratories, Limited	Verfahren zur herstellung von chiralen statin-seitenketten-zwischenprodukten mit candida-antarctica-lipase b
CN103288871A (zh) *	2012-02-28	2013-09-11	浙江京新药业股份有限公司	一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
ITVI20130039A1 (it)	2013-02-20	2014-08-21	F I S Fabbrica Italiana Sint I S P A	Processo per la preparazione di intermedi chiave per la sintesi di statine
CN103172656B (zh) *	2013-04-02	2015-07-08	浙江科技学院	3-二甲基叔丁基硅氧基戊二酸酐的合成工艺
CN111518035A (zh) *	2020-06-18	2020-08-11	安徽鼎旺医药有限公司	一种瑞舒伐他汀叔丁胺盐及其制备方法
CN113683539B (zh) *	2021-09-23	2023-05-16	上海裕兰生物科技有限公司	一种聚酮中间体的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5354772A (en) *	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4650890A (en) *	1984-04-03	1987-03-17	Sandoz Corp.	Preparation of olefinic compounds and intermediates thereof
CA1336714C (en)	1987-08-20	1995-08-15	Yoshihiro Fujikawa	Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja)	1987-08-20	1997-01-08	日産化学工業株式会社	キノリン系メバロノラクトン類
US4804770A (en)	1988-04-29	1989-02-14	E. R. Squibb & Sons, Inc.	Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3911064A1 (de) *	1989-04-06	1990-10-11	Bayer Ag	Substituierte 1,8-naphthyridine
US5049577A (en)	1990-01-29	1991-09-17	E. R. Squibb & Sons, Inc.	2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
ES2072468T3 (es) *	1990-05-11	1995-07-16	American Cyanamid Co	Nuevos arilpirroles n-acilados utiles como agentes insecticidas, acaricidas, nematicidas y molusquicidas.
JP3528186B2 (ja)	1991-06-24	2004-05-17	日産化学工業株式会社	光学活性キノリンメバロン酸のジアステレオマー塩
HRP20030454A2 (en) *	2000-11-16	2005-10-31	Teva Pharmaceutical Industries Ltd.	Hydrolysis of [r(r,r)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
EP1365029A4 (de) *	2001-02-02	2009-07-29	Mitsubishi Chem Corp	"verfahren zur darstellung von (3r,5s)-(e)-7- 2-cyclopropyl-4-(4-fluorphenyl)-chinolin-3-yl -3,5-dihydroxyhept-6-ensäureestern"
US7064209B2 (en) *	2001-11-14	2006-06-20	Nissan Chemical Industries, Ltd.	Process for producing optically active oxoheptenoic acid ester
US6835838B2 (en) *	2002-01-28	2004-12-28	Novartis Ag	Process for the manufacture of organic compounds
GB0210234D0 (en) *	2002-05-03	2002-06-12	Novartis Ag	Process for the manufacture of organic compounds

2003
- 2003-01-30 DE DE60326819T patent/DE60326819D1/de not_active Expired - Lifetime
- 2003-01-30 WO PCT/EP2003/000954 patent/WO2003064392A1/en not_active Ceased
- 2003-01-30 EP EP03734716A patent/EP1472228B1/de not_active Expired - Lifetime
- 2003-01-30 CN CNB038027402A patent/CN1305853C/zh not_active Expired - Lifetime
- 2003-01-30 PL PL03370658A patent/PL370658A1/xx not_active Application Discontinuation
- 2003-01-30 BR BR0307303-3A patent/BR0307303A/pt not_active IP Right Cessation
- 2003-01-30 US US10/502,177 patent/US7371865B2/en not_active Expired - Lifetime
- 2003-01-30 AU AU2003226971A patent/AU2003226971B2/en not_active Ceased
- 2003-01-30 AT AT03734716T patent/ATE426594T1/de active
- 2003-01-30 ES ES03734716T patent/ES2323267T3/es not_active Expired - Lifetime
- 2003-01-30 PT PT03734716T patent/PT1472228E/pt unknown
- 2003-01-30 CA CA2472776A patent/CA2472776C/en not_active Expired - Fee Related
- 2003-01-30 RU RU2004126442/04A patent/RU2299196C2/ru not_active IP Right Cessation
- 2003-01-30 JP JP2003564015A patent/JP4524111B2/ja not_active Expired - Lifetime
- 2003-01-30 MX MXPA04007396A patent/MXPA04007396A/es active IP Right Grant
- 2003-01-30 NZ NZ534232A patent/NZ534232A/xx not_active IP Right Cessation
- 2003-01-30 KR KR10-2004-7011808A patent/KR20040081161A/ko not_active Abandoned
2004
- 2004-07-05 ZA ZA2004/05322A patent/ZA200405322B/en unknown
- 2004-07-12 IL IL162980A patent/IL162980A/en not_active IP Right Cessation
- 2004-07-30 EC EC2004005214A patent/ECSP045214A/es unknown
- 2004-08-10 CO CO04077715A patent/CO5601005A2/es not_active Application Discontinuation
- 2004-08-30 NO NO20043611A patent/NO327091B1/no not_active IP Right Cessation
2008
- 2008-03-24 US US12/054,193 patent/US20080182873A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2299196C2 (ru)	2007-05-20
AU2003226971B2 (en)	2006-11-30
ECSP045214A (es)	2004-09-28
RU2004126442A (ru)	2005-06-10
WO2003064392A1 (en)	2003-08-07
CO5601005A2 (es)	2006-01-31
BR0307303A (pt)	2005-01-11
PT1472228E (pt)	2009-06-24
US20080182873A1 (en)	2008-07-31
US7371865B2 (en)	2008-05-13
CN1622937A (zh)	2005-06-01
JP2005520814A (ja)	2005-07-14
KR20040081161A (ko)	2004-09-20
JP4524111B2 (ja)	2010-08-11
NO327091B1 (no)	2009-04-20
ZA200405322B (en)	2005-07-27
DE60326819D1 (de)	2009-05-07
EP1472228B1 (de)	2009-03-25
PL370658A1 (en)	2005-05-30
ES2323267T3 (es)	2009-07-10
MXPA04007396A (es)	2004-10-11
EP1472228A1 (de)	2004-11-03
CN1305853C (zh)	2007-03-21
CA2472776A1 (en)	2003-08-07
US20050070605A1 (en)	2005-03-31
CA2472776C (en)	2011-01-25
NZ534232A (en)	2006-03-31
NO20043611L (no)	2004-08-30
HK1070651A1 (en)	2005-06-24
IL162980A (en)	2010-02-17

Legal Events

Date

Code

Title

Description

2009-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1472228

Country of ref document: EP

Publication	Publication Date	Title
DE60326819D1 (de)	2009-05-07	Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
ATE450523T1 (de)	2009-12-15	Verfahren zur herstellung von 3-halogen-4,5- dihydro-1 h-pyrazolen
EA201200954A1 (ru)	2013-05-30	Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение
ATE453645T1 (de)	2010-01-15	Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen
MXPA05012268A (es)	2006-02-10	N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
ATE273295T1 (de)	2004-08-15	Verfahren zur herstellung von 6-substituierten (s)-nikotin-derivaten und zwischenverbindungen
MXPA04000357A (es)	2004-05-04	COMPUESTO QUE CONTIENE AMIDA Y TIENE UNA MEJOR SOLUBILIDAD, Y MeTODO PARA MEJORAR LA SOLUBILIDAD DE UN COMPUESTO QUE CONTIENE AMIDA.
EA200301120A1 (ru)	2004-02-26	Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена
EA200300804A1 (ru)	2003-12-25	Усовершенствованный способ получения карбапенема
ATE407127T1 (de)	2008-09-15	Verfahren zur herstellung von beraprost und dessen salzen
ATE354583T1 (de)	2007-03-15	Verfahren zur herstellung c-7 substituierter 5- androstene
NO20062656L (no)	2006-06-09	Fremgangsmate for fremstilling av statiner
EP2266971A3 (de)	2011-04-06	HIV-Protease inhibierende Verbindungen
ATE257832T1 (de)	2004-01-15	Verfahren zur herstellung von citalopram
ATE496038T1 (de)	2011-02-15	Verfahren zur herstellung von quetiapin
ATE521587T1 (de)	2011-09-15	Verfahren zur herstellung von (z)-1-phenyl-1- diethylaminocarbonyl-2- aminomethylcyclopropanhydrochlorid
DE60107292D1 (de)	2004-12-23	Verfahren zur herstellung von (+)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidin
ATE280769T1 (de)	2004-11-15	Verfahren zur herstellung von vitronectin- rezeptorantagonisten
UA85428C2 (ru)	2009-01-26	Способ получения с-2, с-3 замещенных n-алкилированных индолов, а также промежуточные соединения и способы их получения
DE602004008486D1 (de)	2007-10-04	Verfahren zur herstellung von (1s,4r)-cis-4-ä2-amino-6-chlor-9h-purin-9-ylü-2-cyclopenten-1-methanol
ATE496054T1 (de)	2011-02-15	Verfahren zur herstellung von 1,3-dioxolan- nucleosiden
DE602004030091D1 (de)	2010-12-30	Verfahren zur reduktiven deshalogenierung
ATE380183T1 (de)	2007-12-15	Verfahren zur herstellung von phenyltetrazolderivaten
ATE330612T1 (de)	2006-07-15	Verfahren zur herstellung von benazeprilhydrochloride
DE50312447D1 (de)	2010-04-08	Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin